Skip to main content
 
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet 

Investors & Media

Corporate Profile

Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its... More

Recent NewsMore
10/02/17
Seres Therapeutics Reports Positive Topline Results from SER-287 Phase 1b Study in Patients with Ulcerative Colitis
– SER-287 microbiome treatment resulted in a dose-dependent benefit in clinical remission rates, and an improvement in endoscopic scores – – No clinically significant safety or tolerability findings were observed – – Company intends to rapidly advance SER-287 to further development for Ulcerative Colitis – – Conference call scheduled for 8 a.m. today – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 2, 2017-- In the tabl... 
08/31/17
Seres Therapeutics to Present at the Baird 2017 Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 31, 2017-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced it will present at the Baird 2017 Global Healthcare Conference in New York, NY on Wednesday, September 6 at 10:50 a.m. ET. A live audio webcast of the presentation will be available under the “Investors and Media” section of Seres’ website. A replay of the presentation will become available approximately one hour after the event... 
08/03/17
Seres Therapeutics Reports Second Quarter 2017 Financial Results and Provides Update on Operational Progress
... 
EventsMore
There are currently no upcoming events scheduled.
Stock Quote
NASDAQ:MCRB
$10.93
 + 0.12 (1.11%)
10/17/17 4:00 p.m. ET
Refresh quote
E-mail Alerts
Sign up to receive e-mail alerts whenever Seres Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Request Information

Obtain investor relations information by contacting us.

More
Data provided by Nasdaq. Minimum 15 minutes delayed.